Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agree… Read more
Innovation Pharmaceuticals Inc (IPIX) - Total Liabilities
Latest total liabilities as of September 2023: $5.50 Million USD
Based on the latest financial reports, Innovation Pharmaceuticals Inc (IPIX) has total liabilities worth $5.50 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Innovation Pharmaceuticals Inc - Total Liabilities Trend (2007–2023)
This chart illustrates how Innovation Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Innovation Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Innovation Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NISSHIN SEIFUN GRP
DU:NFR
|
Germany | €282.64 Billion |
|
DENTSPLY INTL
MU:DY2
|
Germany | €4.14 Billion |
|
Jura Energy Corporation
PINK:JECFF
|
USA | $24.57 Million |
|
Unibet Group plc
STU:UNBA
|
Germany | €579.30 Million |
Liability Composition Analysis (2007–2023)
This chart breaks down Innovation Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innovation Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innovation Pharmaceuticals Inc (2007–2023)
The table below shows the annual total liabilities of Innovation Pharmaceuticals Inc from 2007 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-06-30 | $5.48 Million | -3.03% |
| 2022-06-30 | $5.65 Million | -16.80% |
| 2021-06-30 | $6.79 Million | -12.79% |
| 2020-06-30 | $7.79 Million | -4.76% |
| 2019-06-30 | $8.18 Million | -5.95% |
| 2018-06-30 | $8.69 Million | -17.81% |
| 2017-06-30 | $10.58 Million | +24.70% |
| 2016-06-30 | $8.48 Million | +16.26% |
| 2015-06-30 | $7.29 Million | -24.37% |
| 2014-06-30 | $9.65 Million | +18.49% |
| 2013-06-30 | $8.14 Million | +6.36% |
| 2012-06-30 | $7.65 Million | +0.70% |
| 2011-06-30 | $7.60 Million | +55.14% |
| 2010-06-30 | $4.90 Million | +151.47% |
| 2009-06-30 | $1.95 Million | +140.01% |
| 2008-06-30 | $811.77K | +17939.27% |
| 2007-06-30 | $4.50K | -- |